---
title: "Ophthalmology concept experiences a volatile rebound, TMSP hits the limit up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250057469.md"
description: "The ophthalmology concept experienced a volatile rebound, with TMSP hitting the limit up, followed by gains in Xingqi Pharmaceutical, Laimei Pharmaceutical, Nosseland, Daheng Technology, Guanhao Biological, and Doctor Glasses"
datetime: "2025-07-25T01:58:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250057469.md)
  - [en](https://longbridge.com/en/news/250057469.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250057469.md)
generator: "portal-rs"
---

# Ophthalmology concept experiences a volatile rebound, TMSP hits the limit up

The ophthalmology concept experienced a volatile rebound, with TMSP hitting the limit up, followed by gains in Xingqi Pharmaceutical, Laimei Pharmaceutical, Nostrand, Daheng Technology, Guanhao Biological, and Doctor Glasses

### Related Stocks

- [300573.CN](https://longbridge.com/en/quote/300573.CN.md)
- [600671.CN](https://longbridge.com/en/quote/600671.CN.md)

## Related News & Research

- [Foura brings wellness dining to Gardens by the Bay](https://longbridge.com/en/news/296454827.md)
- [REG - Hon Hai Prec.Ind.Co - FII AMC MEXICO Announces Land Acquisition](https://longbridge.com/en/news/296208795.md)
- [REG - Origin Enterprises - Holding(s) in Company](https://longbridge.com/en/news/296240027.md)
- [FirstRand Bank lists ZAR 24 million structured product notes on JSE](https://longbridge.com/en/news/296356655.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**